NCT06236763

Comparison of Neuromuscular Recovery at the Hand and Foot

Name: Clinical Trial NCT06236763
Creator: Ciusss de L'Est de l'Île de Montréal
Keywords: Neuromuscular Blockade, TOFscan foot, device, clinical trial, Canada

Comparison of the TOFscan Simultaneous Measures at the Thumb and the First Toe During Recovery of Neuromuscular Function Following Rocuronium Administration

Ciusss de L'Est de l'Île de Montréal·ClinicalTrials.gov·device·Device trialRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Neuromuscular Blockade
Drug/Device/Intervention: TOFscan foot
Study type: Observational
Intervention type: device

Sponsor & location

Primary sponsor: Ciusss de L'Est de l'Île de Montréal
Location: Montréal, Canada

Timeline & enrollment

Phase: N/A
Start date: Mar 01, 2024
End date: Jul 01, 2024
Enrollment: 50 participants

Primary outcome

Time of neuromuscular blockade (NMB) recovery

Summary

Gold standard for neuromuscular blockade evaluation is accelerometry in three dimensions at the thumb. There are many times that measurement at the hand can be falsely under-estimated intraoperatively secondary to constriction of the upper extremities. We believe that installing the same accelerometer at the first toe will give us similar readings for both neuromuscular blockade and recovery from rocuronium administration. This study focuses on agreement values between two accelerometers installed on the hand and at on the foot.

ICD-10 classifications

Skeletal muscle relaxants [neuromuscular blocking agents]Poisoning: Skeletal muscle relaxants [neuromuscular blocking agents]Other neuromuscular dysfunction of bladderNeuromuscular dysfunction of bladder, unspecifiedNeuromuscular scoliosis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06236763
Type: Device Trial

About this record

Access comprehensive clinical trial information for NCT06236763 through Pure Global AI's free database. This phase not specified trial is sponsored by Ciusss de L'Est de l'Île de Montréal and is currently Recruiting. The study focuses on Neuromuscular Blockade. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.